STOCK TITAN

Kamada Ltd - KMDA STOCK NEWS

Welcome to our dedicated news page for Kamada (Ticker: KMDA), a resource for investors and traders seeking the latest updates and insights on Kamada.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Kamada's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Kamada's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.23%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.86%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.46%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.36%
Tags
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.36%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.76%
Tags
conferences
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.96%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.9%
Tags
Kamada Ltd

Nasdaq:KMDA

KMDA Rankings

KMDA Stock Data

295.87M
8.71M
7.32%
49.4%
0.07%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Israel
Rehovot

About KMDA

kamada ltd. is focused on plasma-derived protein therapeutics for orphan indications, and has a commercial product portfolio and a robust late-stage product pipeline. the company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce alpha-1 antitrypsin (aat) in a highly-purified, liquid form, as well as other plasma-derived proteins. aat is a protein derived from human plasma with known and newly-discovered therapeutic roles given its immunomodulatory, anti-inflammatory, tissue-protective and antimicrobial properties. the company’s flagship product is glassia®, the first and only liquid, ready-to-use, intravenous plasma-derived aat product approved by the u.s. food and drug administration. kamada markets glassia in the u.s. through a strategic partnership with baxter international. in addition to glassia, kamada has a product line of nine other pharmaceutical products that are marketed through distributor